STOPGAP II — a national randomized clinical trial for patients with stage 4 gastric cancer - Top-Institutions - MDSpire

STOPGAP II — a national randomized clinical trial for patients with stage 4 gastric cancer

What starts at UCI Health can help shape the national conversation.

June 30, 2026

UCI Health

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

#1

Dana-Farber Cancer Institute

Boston, MA
Key Differentiators
- Oncology
#2

UCI Health

Irvine, CA
Key Differentiators
- Oncology
#3

UC Irvine Anti-Cancer Challenge

Irvine, CA
Key Differentiators
- Oncology
#4

University of Southern California

Los Angeles, CA
Key Differentiators
- Oncology
#5

National Cancer Institute

Bethesda, MD
Key Differentiators
- Oncology

Original Source(s)

UCI Health

STOPGAP II — a national randomized clinical trial for patients with stage 4 gastric cancer

June 30, 2026

Related Content

Jama Network Open

Breast Cancer Incidence in Asian American, Native Hawaiian, and Pacific Islander Populations

by Gregory S. Calip, Kent F. Hoskins, Jenny S. Guadamuz
June 30, 2026

Frontiers In Medicine

Case Report: Synchronous minute intramucosal Epstein–Barr virus-associated gastric cancer revealed after short-term Helicobacter pylori eradication

by Dongqi Wu, Quan Luo, Weiming Wang, Xueman Wang
June 30, 2026

Jama Network Open

Differences in Cascade Genetic Testing Among Families With Hereditary Cancer Risk